

Chemotherapy -overall and by summaries: All Primary cancers

1

			Any chemotherapy				Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	All cases		23558	19032	4364	162	10685	2848	2831	2204	1265	735	1211	1779
	Age at baseline	<18	5290	4424	849	17	2468	824	514	439	262	145	248	390
		18-19	1964	1650	301	13	973	247	236	157	90	67	76	118
		20-24	5470	4485	952	33	2634	638	594	462	292	192	301	357
		25-29	5110	4139	932	39	2248	534	675	552	301	173	269	358
		30-34	3523	2765	728	30	1428	381	523	362	210	98	231	290
		35+	2201	1569	602	30	934	224	289	232	110	60	86	266
	Years since diagnosis	5-9	2383	2042	323	18	880	298	262	215	163	80	142	343
		10-14	7680	6228	1412	40	3329	1096	1042	783	416	230	346	438
		15-19	7552	6140	1357	55	3547	857	924	705	381	236	389	513
		20+	5943	4622	1272	49	2929	597	603	501	305	189	334	485
	Age at diagnosis	<1	1778	1251	519	8	915	202	241	109	74	37	88	112
		1-4	7584	6584	966	34	3988	1041	625	560	331	241	353	445
		5-9	5282	4273	978	31	2453	629	535	520	306	184	284	371
		10-14	4993	3977	977	39	1802	588	796	592	345	167	302	401
		15-20	3921	2947	924	50	1527	388	634	423	209	106	184	450
Males	All cases		12463	10165	2209	89	5345	1522	1593	1213	675	432	714	969
	Age at baseline	<18	2841	2400	430	11	1236	440	289	242	147	84	163	240
		18-19	1014	862	146	6	469	126	139	89	45	44	39	63
		20-24	2840	2322	498	20	1308	321	337	250	159	115	168	182
		25-29	2800	2291	487	22	1160	304	362	340	175	103	159	197
		30-34	1856	1472	369	15	717	214	303	172	101	55	135	159
		35+	1112	818	279	15	455	117	163	120	48	31	50	128
	Years since diagnosis	5-9	1326	1139	175	12	449	170	157	114	92	50	92	202
		10-14	4084	3358	708	18	1678	573	563	450	231	138	210	241
		15-19	3918	3212	674	32	1736	451	521	393	190	142	215	270
		20+	3135	2456	652	27	1482	328	352	256	162	102	197	256
	Age at diagnosis	<1	901	622	274	5	463	102	127	56	34	19	49	51
		1-4	3934	3440	476	18	1943	549	347	308	178	138	215	256
		5-9	2955	2419	515	21	1258	347	345	308	183	117	166	231
		10-14	2603	2088	494	21	905	292	437	317	181	98	171	202
		15-20	2070	1596	450	24	776	232	337	224	99	60	113	229
Females	All cases		11095	8867	2155	73	5340	1326	1238	991	590	303	497	810
	Age at baseline	<18	2449	2024	419	6	1232	384	225	197	115	61	85	150
		18-19	950	788	155	7	504	121	97	68	45	23	37	55
		20-24	2630	2163	454	13	1326	317	257	212	133	77	133	175
		25-29	2310	1848	445	17	1088	230	313	212	126	70	110	161
		30-34	1667	1293	359	15	711	167	220	190	109	43	96	131
		35+	1089	751	323	15	479	107	126	112	62	29	36	138
	Years since diagnosis	5-9	1057	903	148	6	431	128	105	101	71	30	50	141
		10-14	3596	2870	704	22	1651	523	479	333	185	92	136	197
		15-19	3634	2928	683	23	1811	406	403	312	191	94	174	243
		20+	2808	2166	620	22	1447	269	251	245	143	87	137	229

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines ²					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	All cases		23558	12085	2149	4639	2468	1287	930
	Age at baseline	<18	5290	2785	618	1043	466	181	197
		18-19	1964	1041	200	395	180	78	70
		20-24	5470	2895	537	1025	541	277	195
		25-29	5110	2562	421	1081	549	295	202
		30-34	3523	1658	254	729	453	283	146
		35+	2201	1144	119	366	279	173	120
	Years since diagnosis	5-9	2383	1041	260	435	327	158	162
		10-14	7680	3779	693	1760	802	390	256
		15-19	7552	3776	720	1512	792	478	274
		20+	5943	3489	476	932	547	261	238
	Age at diagnosis	<1	1778	1132	173	307	74	46	46
		1-4	7584	4134	912	1403	644	238	253
		5-9	5282	2879	467	956	523	261	196
		10-14	4993	2203	380	1146	678	376	210
		15-20	3921	1737	217	827	549	366	225
Males	All cases		12463	6260	1143	2558	1288	707	507
	Age at baseline	<18	2841	1437	331	593	248	104	128
		18-19	1014	522	106	219	91	38	38
		20-24	2840	1491	270	547	284	151	97
		25-29	2800	1416	229	615	275	167	98
		30-34	1856	838	141	386	247	157	87
		35+	1112	556	66	198	143	90	59
	Years since diagnosis	5-9	1326	554	130	269	177	95	101
		10-14	4084	1975	381	953	410	229	136
		15-19	3918	1927	389	793	431	237	141
		20+	3135	1804	243	543	270	146	129
	Age at diagnosis	<1	901	574	87	164	33	17	26
		1-4	3934	2090	479	742	347	137	139
		5-9	2955	1571	252	601	266	144	121
		10-14	2603	1139	187	621	343	203	110
		15-20	2070	886	138	430	299	206	111
Females	All cases		11095	5825	1006	2081	1180	580	423
	Age at baseline	<18	2449	1348	287	450	218	77	69
		18-19	950	519	94	176	89	40	32
		20-24	2630	1404	267	478	257	126	98
		25-29	2310	1146	192	466	274	128	104
		30-34	1667	820	113	343	206	126	59
		35+	1089	588	53	168	136	83	61
	Years since diagnosis	5-9	1057	487	130	166	150	63	61
		10-14	3596	1804	312	807	392	161	120
		15-19	3634	1849	331	719	361	241	133
		20+	2808	1685	233	389	277	115	109

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
	Age at diagnosis	<1	877	629	245	3	452	100	114	53	40	18	39	61
		1-4	3650	3144	490	16	2045	492	278	252	153	103	138	189
		5-9	2327	1854	463	10	1195	282	190	212	123	67	118	140
		10-14	2390	1889	483	18	897	296	359	275	164	69	131	199
		15-20	1851	1351	474	26	751	156	297	199	110	46	71	221

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Anthracyclines ²						
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
	Age at diagnosis	<1	877	558	86	143	41	29	20
		1-4	3650	2044	433	661	297	101	114
		5-9	2327	1308	215	355	257	117	75
		10-14	2390	1064	193	525	335	173	100
		15-20	1851	851	79	397	250	160	114

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Any chemotherapy				Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	All cases	<18	7245	7183	18	44	3147	1768	740	623	183	110	141	533
	Age at baseline	<18	2096	2083	6	7	797	609	193	197	55	32	30	183
		18-19	769	761	3	5	353	182	93	58	18	8	9	48
		20-24	1788	1775	3	10	890	418	161	141	28	20	26	104
		25-29	1459	1449	2	8	646	314	159	136	42	29	41	92
		30-34	761	747	3	11	328	165	95	54	23	14	24	58
		35+	372	368	1	3	133	80	39	37	17	7	11	48
	Years since diagnosis	5-9	904	897	2	5	318	224	75	92	30	10	19	136
		10-14	2445	2424	6	15	902	726	304	228	65	45	38	137
		15-19	2236	2219	5	12	1106	502	247	171	45	16	21	128
		20+	1660	1643	5	12	821	316	114	132	43	39	63	132
	Age at diagnosis	<1	232	227	4	1	78	53	38	24	8	1	7	23
		1-4	3421	3400	8	13	1634	861	279	260	65	48	54	220
		5-9	1754	1738	2	14	823	402	150	145	43	30	34	127
		10-14	1203	1195	2	6	400	314	164	134	43	22	36	90
		15-20	635	623	2	10	212	138	109	60	24	9	10	73
Males	All cases	<18	3827	3790	11	26	1588	932	407	341	95	64	95	305
	Age at baseline	<18	1136	1126	5	5	413	325	96	105	33	20	21	123
		18-19	411	408	2	1	185	93	57	29	9	6	7	25
		20-24	891	884	2	5	432	208	87	74	12	12	17	49
		25-29	783	776	1	6	327	175	86	81	21	15	30	48
		30-34	397	389	.	8	156	83	60	28	11	9	14	36
		35+	209	207	1	1	75	48	21	24	9	2	6	24
	Years since diagnosis	5-9	510	506	1	3	164	127	45	45	15	8	13	93
		10-14	1301	1290	4	7	473	378	147	128	42	31	29	73
		15-19	1136	1123	4	9	533	253	145	100	15	8	16	66
		20+	880	871	2	7	418	174	70	68	23	17	37	73
	Age at diagnosis	<1	110	105	4	1	35	23	22	12	6	.	2	10
		1-4	1809	1797	5	7	828	464	149	140	28	23	42	135
		5-9	935	925	1	9	416	203	92	80	29	23	20	72
		10-14	588	584	.	4	183	152	84	70	19	11	23	46
		15-20	385	379	1	5	126	90	60	39	13	7	8	42
Females	All cases	<18	3418	3393	7	18	1559	836	333	282	88	46	46	228
	Age at baseline	<18	960	957	1	2	384	284	97	92	22	12	9	60
		18-19	358	353	1	4	168	89	36	29	9	2	2	23
		20-24	897	891	1	5	458	210	74	67	16	8	9	55
		25-29	676	673	1	2	319	139	73	55	21	14	11	44
		30-34	364	358	3	3	172	82	35	26	12	5	10	22
		35+	163	161	.	2	58	32	18	13	8	5	5	24
	Years since diagnosis	5-9	394	391	1	2	154	97	30	47	15	2	6	43
		10-14	1144	1134	2	8	429	348	157	100	23	14	9	64
		15-19	1100	1096	1	3	573	249	102	71	30	8	5	62
		20+	780	772	3	5	403	142	44	64	20	22	26	59
	Age at diagnosis	<1	122	122	.	.	43	30	16	12	2	1	5	13
		1-4	1612	1603	3	6	806	397	130	120	37	25	12	85

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Anthracyclines ²						
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	All cases	7245	2708	1605	1753	494	323	362	
	Age at baseline	<18	2096	810	459	486	135	93	113
		18-19	769	308	154	194	57	28	28
		20-24	1788	686	435	399	98	80	90
		25-29	1459	538	314	378	108	60	61
		30-34	761	256	166	195	66	41	37
		35+	372	110	77	101	30	21	33
	Years since diagnosis	5-9	904	278	223	218	62	42	81
		10-14	2445	912	494	683	167	88	101
		15-19	2236	768	523	538	176	138	93
		20+	1660	750	365	314	89	55	87
	Age at diagnosis	<1	232	40	76	71	17	14	14
		1-4	3421	1482	767	696	194	131	151
		5-9	1754	721	363	385	115	85	85
		10-14	1203	317	272	396	106	53	59
		15-20	635	148	127	205	62	40	53
Males	All cases	3827	1325	845	974	280	188	215	
	Age at baseline	<18	1136	396	253	269	75	60	83
		18-19	411	152	82	112	35	13	17
		20-24	891	322	212	209	59	44	45
		25-29	783	287	163	220	54	35	24
		30-34	397	114	91	99	39	26	28
		35+	209	54	44	65	18	10	18
	Years since diagnosis	5-9	510	137	114	140	37	27	55
		10-14	1301	451	269	369	93	60	59
		15-19	1136	358	277	278	105	67	51
		20+	880	379	185	187	45	34	50
	Age at diagnosis	<1	110	18	38	33	5	5	11
		1-4	1809	736	406	383	114	78	92
		5-9	935	345	192	229	64	51	54
		10-14	588	144	123	204	61	30	26
		15-20	385	82	86	125	36	24	32
Females	All cases	3418	1383	760	779	214	135	147	
	Age at baseline	<18	960	414	206	217	60	33	30
		18-19	358	156	72	82	22	15	11
		20-24	897	364	223	190	39	36	45
		25-29	676	251	151	158	54	25	37
		30-34	364	142	75	96	27	15	9
		35+	163	56	33	36	12	11	15
	Years since diagnosis	5-9	394	141	109	78	25	15	26
		10-14	1144	461	225	314	74	28	42
		15-19	1100	410	246	260	71	71	42
		20+	780	371	180	127	44	21	37
	Age at diagnosis	<1	122	22	38	38	12	9	3
		1-4	1612	746	361	313	80	53	59

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	819	813	1	5	407	199	58	65	14	7	14	55
		10-14	615	611	2	2	217	162	80	64	24	11	13	44
		15-20	250	244	1	5	86	48	49	21	11	2	2	31

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide
² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines ²					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	819	376	171	156	51	34	31
		10-14	615	173	149	192	45	23	33
		15-20	250	66	41	80	26	16	21

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	All cases		6067	6024	7	36	2683	1484	586	533	140	90	123	428
	Age at baseline	<18	1812	1802	3	7	691	517	160	181	43	28	29	163
		18-19	666	662	.	4	313	155	76	54	16	7	8	37
		20-24	1524	1514	1	9	776	359	119	127	25	16	21	81
		25-29	1207	1202	.	5	556	259	126	107	28	25	37	69
		30-34	590	579	2	9	259	133	78	34	14	8	21	43
		35+	268	265	1	2	88	61	27	30	14	6	7	35
	Years since diagnosis	5-9	777	771	2	4	276	182	58	89	28	9	17	118
		10-14	2049	2036	1	12	747	616	246	198	52	38	37	115
		15-19	1847	1835	1	11	949	416	195	141	25	11	15	95
		20+	1394	1382	3	9	711	270	87	105	35	32	54	100
	Age at diagnosis	<1	127	126	.	1	40	29	17	18	5	.	7	11
		1-4	3030	3014	5	11	1470	753	235	235	51	42	46	198
		5-9	1537	1524	.	13	736	351	122	125	38	26	33	106
		10-14	940	937	1	2	308	250	133	110	31	15	32	61
		15-20	433	423	1	9	129	101	79	45	15	7	5	52
Males	All cases		3231	3206	4	21	1353	785	325	297	76	52	85	258
	Age at baseline	<18	982	975	2	5	353	274	78	99	27	18	21	112
		18-19	359	358	.	1	163	79	48	27	8	5	7	22
		20-24	759	753	1	5	382	176	61	67	11	9	14	39
		25-29	660	657	.	3	277	149	71	67	16	14	28	38
		30-34	313	306	.	7	128	66	50	18	6	4	13	28
		35+	158	157	1	.	50	41	17	19	8	2	2	19
	Years since diagnosis	5-9	440	436	1	3	141	106	34	44	13	7	13	82
		10-14	1099	1093	1	5	396	316	118	113	35	27	28	66
		15-19	949	939	1	9	462	211	117	85	9	4	11	50
		20+	743	738	1	4	354	152	56	55	19	14	33	60
	Age at diagnosis	<1	63	62	.	1	22	12	11	9	3	.	2	4
		1-4	1591	1582	3	6	731	401	124	128	25	19	38	125
		5-9	829	821	.	8	369	181	76	73	26	20	20	64
		10-14	476	475	.	1	146	121	72	58	14	8	22	35
		15-20	272	266	1	5	85	70	42	29	8	5	3	30
Females	All cases		2836	2818	3	15	1330	699	261	236	64	38	38	170
	Age at baseline	<18	830	827	1	2	338	243	82	82	16	10	8	51
		18-19	307	304	.	3	150	76	28	27	8	2	1	15
		20-24	765	761	.	4	394	183	58	60	14	7	7	42
		25-29	547	545	.	2	279	110	55	40	12	11	9	31
		30-34	277	273	2	2	131	67	28	16	8	4	8	15
		35+	110	108	.	2	38	20	10	11	6	4	5	16
	Years since diagnosis	5-9	337	335	1	1	135	76	24	45	15	2	4	36
		10-14	950	943	.	7	351	300	128	85	17	11	9	49
		15-19	898	896	.	2	487	205	78	56	16	7	4	45
		20+	651	644	2	5	357	118	31	50	16	18	21	40
	Age at diagnosis	<1	64	64	.	.	18	17	6	9	2	.	5	7
		1-4	1439	1432	2	5	739	352	111	107	26	23	8	73

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines ²					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	All cases		6067	2485	1422	1256	413	205	286
	Age at baseline	<18	1812	768	408	366	117	56	97
		18-19	666	291	141	149	47	14	24
		20-24	1524	645	400	275	81	55	68
		25-29	1207	488	277	267	88	39	48
		30-34	590	214	139	130	54	25	28
		35+	268	79	57	69	26	16	21
	Years since diagnosis	5-9	777	239	207	175	49	36	71
		10-14	2049	850	429	503	138	46	83
		15-19	1847	713	468	373	148	74	71
		20+	1394	683	318	205	78	49	61
	Age at diagnosis	<1	127	24	57	25	9	3	9
		1-4	3030	1427	702	519	173	81	128
		5-9	1537	683	339	284	101	63	67
		10-14	940	261	219	296	85	36	43
		15-20	433	90	105	132	45	22	39
Males	All cases		3231	1223	753	716	240	125	174
	Age at baseline	<18	982	375	227	209	64	36	71
		18-19	359	145	76	84	32	8	14
		20-24	759	307	192	144	48	35	33
		25-29	660	258	145	164	50	23	20
		30-34	313	95	80	69	32	15	22
		35+	158	43	33	46	14	8	14
	Years since diagnosis	5-9	440	120	106	114	29	21	50
		10-14	1099	419	238	279	78	35	50
		15-19	949	333	249	196	93	39	39
		20+	743	351	160	127	40	30	35
	Age at diagnosis	<1	63	9	30	14	2	1	7
		1-4	1591	710	367	287	103	49	75
		5-9	829	330	181	173	59	41	45
		10-14	476	120	104	159	50	23	20
		15-20	272	54	71	83	26	11	27
Females	All cases		2836	1262	669	540	173	80	112
	Age at baseline	<18	830	393	181	157	53	20	26
		18-19	307	146	65	65	15	6	10
		20-24	765	338	208	131	33	20	35
		25-29	547	230	132	103	38	16	28
		30-34	277	119	59	61	22	10	6
		35+	110	36	24	23	12	8	7
	Years since diagnosis	5-9	337	119	101	61	20	15	21
		10-14	950	431	191	224	60	11	33
		15-19	898	380	219	177	55	35	32
		20+	651	332	158	78	38	19	26
	Age at diagnosis	<1	64	15	27	11	7	2	2
		1-4	1439	717	335	232	70	32	53

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Any chemotherapy			Alkylating agent (CED, mg/m2) ¹							
		All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
	5-9	708	703	.	5	367	170	46	52	12	6	13	42
	10-14	464	462	1	1	162	129	61	52	17	7	10	26
	15-20	161	157	.	4	44	31	37	16	7	2	2	22

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Anthracyclines ²						
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	708	353	158	111	42	22	22
		10-14	464	141	115	137	35	13	23
		15-20	161	36	34	49	19	11	12

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Any chemotherapy				Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	All cases		871	860	6	5	366	194	119	67	35	13	11	66
	Age at baseline	<18	225	223	2	.	88	70	30	14	10	3	1	9
		18-19	82	79	2	1	31	19	15	4	2	1	1	9
		20-24	191	189	1	1	89	40	30	9	2	3	2	16
		25-29	186	185	.	1	70	37	28	21	10	3	3	14
		30-34	118	116	1	1	50	19	9	16	8	3	3	10
		35+	69	68	.	1	38	9	7	3	3	.	1	8
	Years since diagnosis	5-9	81	80	.	1	26	31	14	.	1	.	2	7
		10-14	307	303	3	1	131	78	43	22	13	6	1	13
		15-19	301	298	2	1	129	59	42	25	16	3	3	24
		20+	182	179	1	2	80	26	20	20	5	4	5	22
	Age at diagnosis	<1	90	87	3	.	33	18	20	6	3	1	.	9
		1-4	299	297	1	1	128	79	38	22	11	4	4	13
		5-9	163	161	1	1	70	37	21	15	1	3	1	15
		10-14	182	179	.	3	69	39	21	17	11	5	4	16
		15-20	137	136	1	.	66	21	19	7	9	.	2	13
Males	All cases		427	421	3	3	186	100	60	29	14	6	5	27
	Age at baseline	<18	122	120	2	.	52	41	15	5	4	1	.	4
		18-19	42	41	1	.	17	10	8	2	1	1	.	3
		20-24	92	92	.	.	38	22	18	5	1	2	1	5
		25-29	82	81	.	1	38	16	11	8	3	.	2	4
		30-34	56	55	.	1	21	9	5	7	4	2	1	7
		35+	33	32	.	1	20	2	3	2	1	.	1	4
	Years since diagnosis	5-9	47	47	.	.	16	16	9	.	1	.	.	5
		10-14	152	149	2	1	69	45	17	8	7	3	1	2
		15-19	141	140	1	.	55	31	23	14	4	2	2	10
		20+	87	85	.	2	46	8	11	7	2	1	2	10
	Age at diagnosis	<1	39	36	3	.	12	8	10	3	3	.	.	3
		1-4	165	165	.	.	77	46	21	10	2	2	2	5
		5-9	75	74	.	1	35	18	11	4	.	2	.	5
		10-14	74	72	.	2	29	17	6	8	4	2	1	7
		15-20	74	74	.	.	33	11	12	4	5	.	2	7
Females	All cases		444	439	3	2	180	94	59	38	21	7	6	39
	Age at baseline	<18	103	103	.	.	36	29	15	9	6	2	1	5
		18-19	40	38	1	1	14	9	7	2	1	.	1	6
		20-24	99	97	1	1	51	18	12	4	1	1	1	11
		25-29	104	104	.	.	32	21	17	13	7	3	1	10
		30-34	62	61	1	.	29	10	4	9	4	1	2	3
		35+	36	36	.	.	18	7	4	1	2	.	.	4
	Years since diagnosis	5-9	34	33	.	1	10	15	5	.	.	.	2	2
		10-14	155	154	1	.	62	33	26	14	6	3	.	11
		15-19	160	158	1	1	74	28	19	11	12	1	1	14
		20+	95	94	1	.	34	18	9	13	3	3	3	12
	Age at diagnosis	<1	51	51	.	.	21	10	10	3	.	1	.	6
		1-4	134	132	1	1	51	33	17	12	9	2	2	8

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Anthracyclines ²						
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	All cases		871	58	152	436	68	100	57
	Age at baseline	<18	225	13	45	109	13	33	12
		18-19	82	7	11	37	10	13	4
		20-24	191	8	25	107	13	20	18
		25-29	186	8	33	101	18	17	9
		30-34	118	12	21	56	12	12	5
		35+	69	10	17	26	2	5	9
	Years since diagnosis	5-9	81	5	15	39	9	4	9
		10-14	307	13	55	164	26	36	13
		15-19	301	15	47	140	25	57	17
		20+	182	25	35	93	8	3	18
	Age at diagnosis	<1	90	11	18	43	6	11	1
		1-4	299	14	51	154	18	43	19
		5-9	163	11	21	87	11	18	15
		10-14	182	9	42	88	17	14	12
		15-20	137	13	20	64	16	14	10
Males	All cases		427	26	76	211	32	53	29
	Age at baseline	<18	122	8	23	51	9	22	9
		18-19	42	4	5	22	3	5	3
		20-24	92	2	14	53	8	7	8
		25-29	82	3	15	49	3	10	2
		30-34	56	5	10	23	7	7	4
		35+	33	4	9	13	2	2	3
	Years since diagnosis	5-9	47	3	7	22	6	4	5
		10-14	152	5	28	78	13	22	6
		15-19	141	9	24	65	10	24	9
		20+	87	9	17	46	3	3	9
	Age at diagnosis	<1	39	6	8	17	3	4	1
		1-4	165	7	30	78	9	28	13
		5-9	75	4	9	46	3	7	6
		10-14	74	5	15	36	8	5	5
		15-20	74	4	14	34	9	9	4
Females	All cases		444	32	76	225	36	47	28
	Age at baseline	<18	103	5	22	58	4	11	3
		18-19	40	3	6	15	7	8	1
		20-24	99	6	11	54	5	13	10
		25-29	104	5	18	52	15	7	7
		30-34	62	7	11	33	5	5	1
		35+	36	6	8	13	.	3	6
	Years since diagnosis	5-9	34	2	8	17	3	.	4
		10-14	155	8	27	86	13	14	7
		15-19	160	6	23	75	15	33	8
		20+	95	16	18	47	5	.	9
	Age at diagnosis	<1	51	5	10	26	3	7	.
		1-4	134	7	21	76	9	15	6

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	88	87	1	.	35	19	10	11	1	1	1	10
		10-14	108	107	.	1	40	22	15	9	7	3	3	9
		15-20	63	62	1	.	33	10	7	3	4	.	.	6

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Anthracyclines ²						
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	88	7	12	41	8	11	9
		10-14	108	4	27	52	9	9	7
		15-20	63	9	6	30	7	5	6

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Any chemotherapy				Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	All cases		4184	1618	2528	38	2947	109	154	318	228	111	113	204
	Age at baseline	<18	891	440	447	4	552	24	41	68	70	29	45	62
		18-19	349	165	178	6	234	6	18	27	19	12	15	18
		20-24	1093	439	645	9	744	37	40	88	58	41	29	56
		25-29	1021	368	642	11	736	26	34	88	62	17	15	43
		30-34	581	155	424	2	466	15	15	39	13	9	6	18
		35+	249	51	192	6	215	1	6	8	6	3	3	7
	Years since diagnosis	5-9	428	218	205	5	235	10	15	32	49	15	19	53
		10-14	1424	559	855	10	1006	35	63	127	73	34	33	53
		15-19	1325	509	801	15	946	34	51	92	59	42	43	58
		20+	1007	332	667	8	760	30	25	67	47	20	18	40
	Age at diagnosis	<1	205	120	84	1	119	7	15	7	11	9	23	14
		1-4	1223	554	660	9	819	36	39	81	78	50	57	63
		5-9	1326	518	799	9	914	42	54	132	77	29	15	63
		10-14	996	312	674	10	751	22	37	76	45	17	10	38
		15-20	434	114	311	9	344	2	9	22	17	6	8	26
Males	All cases		2276	942	1309	25	1542	50	89	193	135	74	68	125
	Age at baseline	<18	494	258	232	4	281	13	27	39	43	21	32	38
		18-19	176	84	88	4	119	3	10	15	8	5	6	10
		20-24	584	260	320	4	375	16	24	56	36	27	19	31
		25-29	579	229	345	5	404	13	17	59	40	13	7	26
		30-34	309	81	226	2	252	5	6	19	6	5	3	13
		35+	134	30	98	6	111	.	5	5	2	3	1	7
	Years since diagnosis	5-9	242	123	115	4	131	5	11	17	26	10	11	31
		10-14	766	329	432	5	508	18	35	79	47	24	22	33
		15-19	720	301	409	10	493	15	30	57	37	27	25	36
		20+	548	189	353	6	410	12	13	40	25	13	10	25
	Age at diagnosis	<1	121	72	48	1	67	4	12	2	5	7	18	6
		1-4	647	309	333	5	411	16	19	54	47	33	35	32
		5-9	738	322	411	5	485	20	32	79	48	19	8	47
		10-14	526	174	345	7	388	9	21	47	27	10	2	22
		15-20	244	65	172	7	191	1	5	11	8	5	5	18
Females	All cases		1908	676	1219	13	1405	59	65	125	93	37	45	79
	Age at baseline	<18	397	182	215	.	271	11	14	29	27	8	13	24
		18-19	173	81	90	2	115	3	8	12	11	7	9	8
		20-24	509	179	325	5	369	21	16	32	22	14	10	25
		25-29	442	139	297	6	332	13	17	29	22	4	8	17
		30-34	272	74	198	.	214	10	9	20	7	4	3	5
		35+	115	21	94	.	104	1	1	3	4	.	2	.
	Years since diagnosis	5-9	186	95	90	1	104	5	4	15	23	5	8	22
		10-14	658	230	423	5	498	17	28	48	26	10	11	20
		15-19	605	208	392	5	453	19	21	35	22	15	18	22
		20+	459	143	314	2	350	18	12	27	22	7	8	15
	Age at diagnosis	<1	84	48	36	.	52	3	3	5	6	2	5	8

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines ²				
			All cases	None	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	All cases		4184	4120	13	17	3	31
	Age at baseline	<18	891	883	1	2	1	4
		18-19	349	345	.	1	.	3
		20-24	1093	1074	5	4	2	8
		25-29	1021	1002	4	4	.	11
		30-34	581	571	3	5	.	2
		35+	249	245	.	1	.	3
	Years since diagnosis	5-9	428	422	2	1	.	3
		10-14	1424	1410	6	1	1	6
		15-19	1325	1293	4	11	2	15
		20+	1007	995	1	4	.	7
	Age at diagnosis	<1	205	204	.	.	1	.
		1-4	1223	1207	2	4	1	9
		5-9	1326	1304	3	8	1	10
		10-14	996	980	5	3	.	8
		15-20	434	425	3	2	.	4
Males	All cases		2276	2238	7	9	2	20
	Age at baseline	<18	494	488	1	1	1	3
		18-19	176	175	.	.	.	1
		20-24	584	572	3	3	1	5
		25-29	579	569	2	2	.	6
		30-34	309	303	1	3	.	2
		35+	134	131	.	.	.	3
	Years since diagnosis	5-9	242	238	1	1	.	2
		10-14	766	758	4	1	1	2
		15-19	720	701	2	5	1	11
		20+	548	541	.	2	.	5
	Age at diagnosis	<1	121	120	.	.	1	.
		1-4	647	642	.	1	.	4
		5-9	738	722	3	5	1	7
		10-14	526	516	2	2	.	6
		15-20	244	238	2	1	.	3
Females	All cases		1908	1882	6	8	1	11
	Age at baseline	<18	397	395	.	1	.	1
		18-19	173	170	.	1	.	2
		20-24	509	502	2	1	1	3
		25-29	442	433	2	2	.	5
		30-34	272	268	2	2	.	.
		35+	115	114	.	1	.	.
	Years since diagnosis	5-9	186	184	1	.	.	1
		10-14	658	652	2	.	.	4
		15-19	605	592	2	6	1	4
		20+	459	454	1	2	.	2
	Age at diagnosis	<1	84	84

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		1-4	576	245	327	4	408	20	20	27	31	17	22	31
		5-9	588	196	388	4	429	22	22	53	29	10	7	16
		10-14	470	138	329	3	363	13	16	29	18	7	8	16
		15-20	190	49	139	2	153	1	4	11	9	1	3	8

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines ²				
			All cases	None	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		1-4	576	565	2	3	1	5
		5-9	588	582	.	3	.	3
		10-14	470	464	3	1	.	2
		15-20	190	187	1	1	.	1

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Any chemotherapy			Alkylating agent (CED, mg/m2) ¹								
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	All cases		2509	633	1855	21	2147	42	38	66	67	26	34	89
	Age at baseline	<18	493	180	311	2	393	10	10	15	20	9	12	24
		18-19	202	70	129	3	171	3	3	6	8	1	4	6
		20-24	662	164	491	7	566	12	13	13	14	8	11	25
		25-29	629	143	480	6	546	12	6	19	16	5	5	20
		30-34	357	55	301	1	318	4	4	10	7	2	1	11
		35+	166	21	143	2	153	1	2	3	2	1	1	3
	Years since diagnosis	5-9	219	77	141	1	159	4	5	11	16	5	4	15
		10-14	838	231	600	7	718	13	13	24	24	7	11	28
		15-19	778	184	585	9	682	15	10	13	14	7	10	27
		20+	674	141	529	4	588	10	10	18	13	7	9	19
	Age at diagnosis	<1	144	82	62	.	94	6	8	3	7	5	12	9
		1-4	741	228	506	7	633	12	10	15	21	11	13	26
		5-9	750	158	586	6	658	12	7	24	16	3	4	26
		10-14	599	108	487	4	528	11	10	16	12	4	2	16
		15-20	275	57	214	4	234	1	3	8	11	3	3	12
Males	All cases		1302	357	934	11	1086	22	23	27	40	23	20	61
	Age at baseline	<18	258	104	152	2	189	5	6	7	16	8	10	17
		18-19	102	36	64	2	86	2	3	3	2	1	1	4
		20-24	325	92	231	2	270	8	8	6	7	6	5	15
		25-29	351	87	262	2	301	6	3	10	10	5	3	13
		30-34	178	25	152	1	162	1	1	.	3	2	.	9
		35+	88	13	73	2	78	.	2	1	2	1	1	3
	Years since diagnosis	5-9	117	41	76	.	85	2	5	4	8	4	3	6
		10-14	437	136	298	3	357	7	5	12	19	7	8	22
		15-19	391	100	285	6	335	9	6	5	6	7	4	19
		20+	357	80	275	2	309	4	7	6	7	5	5	14
	Age at diagnosis	<1	81	50	31	.	47	4	7	2	3	4	8	6
		1-4	373	124	246	3	304	7	6	9	14	10	7	16
		5-9	394	96	294	4	340	6	4	9	10	2	3	20
		10-14	302	56	244	2	265	5	5	4	8	4	.	11
		15-20	152	31	119	2	130	.	1	3	5	3	2	8
Females	All cases		1207	276	921	10	1061	20	15	39	27	3	14	28
	Age at baseline	<18	235	76	159	.	204	5	4	8	4	1	2	7
		18-19	100	34	65	1	85	1	.	3	6	.	3	2
		20-24	337	72	260	5	296	4	5	7	7	2	6	10
		25-29	278	56	218	4	245	6	3	9	6	.	2	7
		30-34	179	30	149	.	156	3	3	10	4	.	1	2
		35+	78	8	70	.	75	1	.	2
	Years since diagnosis	5-9	102	36	65	1	74	2	.	7	8	1	1	9
		10-14	401	95	302	4	361	6	8	12	5	.	3	6
		15-19	387	84	300	3	347	6	4	8	8	.	6	8
		20+	317	61	254	2	279	6	3	12	6	2	4	5
	Age at diagnosis	<1	63	32	31	.	47	2	1	1	4	1	4	3
		1-4	368	104	260	4	329	5	4	6	7	1	6	10

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Anthracyclines ²					
			All cases	None	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	All cases		2509	2485	4	1	1	18
	Age at baseline	<18	493	491	.	.	.	2
		18-19	202	200	.	.	.	2
		20-24	662	651	4	1	1	5
		25-29	629	622	.	.	.	7
		30-34	357	356	.	.	.	1
		35+	166	165	.	.	.	1
	Years since diagnosis	5-9	219	218	1	.	.	.
		10-14	838	831	2	.	.	5
		15-19	778	767	1	1	1	8
		20+	674	669	.	.	.	5
	Age at diagnosis	<1	144	144
		1-4	741	733	1	.	.	7
		5-9	750	741	1	1	1	6
		10-14	599	595	1	.	.	3
		15-20	275	272	1	.	.	2
Males	All cases		1302	1288	2	1	1	10
	Age at baseline	<18	258	256	.	.	.	2
		18-19	102	101	.	.	.	1
		20-24	325	319	2	1	1	2
		25-29	351	348	.	.	.	3
		30-34	178	177	.	.	.	1
		35+	88	87	.	.	.	1
	Years since diagnosis	5-9	117	117
		10-14	437	433	2	.	.	2
		15-19	391	384	.	1	1	5
		20+	357	354	.	.	.	3
	Age at diagnosis	<1	81	81
		1-4	373	370	.	.	.	3
		5-9	394	387	1	1	1	4
		10-14	302	299	1	.	.	2
		15-20	152	151	.	.	.	1
Females	All cases		1207	1197	2	.	.	8
	Age at baseline	<18	235	235
		18-19	100	99	.	.	.	1
		20-24	337	332	2	.	.	3
		25-29	278	274	.	.	.	4
		30-34	179	179
		35+	78	78
	Years since diagnosis	5-9	102	101	1	.	.	.
		10-14	401	398	.	.	.	3
		15-19	387	383	1	.	.	3
		20+	317	315	.	.	.	2
	Age at diagnosis	<1	63	63
		1-4	368	363	1	.	.	4

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Any chemotherapy			Alkylating agent (CED, mg/m2) ¹							
		All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
	5-9	356	62	292	2	318	6	3	15	6	1	1	6
	10-14	297	52	243	2	263	6	5	12	4	.	2	5
	15-20	123	26	95	2	104	1	2	5	6	.	1	4

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines ²				
			All cases	None	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	356	354	.	.	.	2
		10-14	297	296	.	.	.	1
		15-20	123	121	1	.	.	1

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	All cases		979	750	218	11	280	55	94	211	125	66	60	88
	Age at baseline	<18	233	184	47	2	56	11	24	38	33	14	25	32
		18-19	77	59	15	3	19	2	9	19	7	6	7	8
		20-24	273	221	50	2	60	21	24	66	39	27	12	24
		25-29	236	183	51	2	68	11	25	60	37	10	9	16
		30-34	126	85	41	.	58	10	10	25	6	7	5	5
		35+	34	18	14	2	19	.	2	3	3	2	2	3
	Years since diagnosis	5-9	119	98	17	4	22	3	7	17	24	6	13	27
		10-14	333	259	72	2	84	17	42	85	40	25	18	22
		15-19	323	243	77	3	99	17	31	70	34	25	23	24
		20+	204	150	52	2	75	18	14	39	27	10	6	15
	Age at diagnosis	<1	23	19	3	1	4	1	4	2	1	1	7	3
		1-4	279	221	56	2	69	18	21	49	36	24	31	31
		5-9	402	308	92	2	117	29	42	97	55	25	9	28
		10-14	217	164	50	3	68	7	23	53	28	13	8	17
		15-20	58	38	17	3	22	.	4	10	5	3	5	9
Males	All cases		599	468	122	9	169	24	55	148	80	41	33	49
	Age at baseline	<18	141	114	25	2	32	6	18	27	20	7	14	17
		18-19	43	33	8	2	12	1	4	12	3	3	3	5
		20-24	177	143	32	2	38	8	14	47	29	19	10	12
		25-29	145	120	24	1	38	5	13	44	25	7	3	10
		30-34	71	47	24	.	36	4	4	16	3	3	3	2
		35+	22	11	9	2	13	.	2	2	.	2	.	3
	Years since diagnosis	5-9	72	58	10	4	14	1	5	12	15	2	6	17
		10-14	196	161	34	1	42	9	25	60	24	15	11	10
		15-19	207	157	48	2	66	6	19	48	24	17	13	14
		20+	124	92	30	2	47	8	6	28	17	7	3	8
	Age at diagnosis	<1	16	12	3	1	4	.	4	.	1	1	6	.
		1-4	168	137	29	2	40	7	9	40	24	16	17	15
		5-9	257	200	56	1	74	14	26	65	36	16	5	21
		10-14	123	96	25	2	38	3	14	37	16	6	2	7
		15-20	35	23	9	3	13	.	2	6	3	2	3	6
Females	All cases		380	282	96	2	111	31	39	63	45	25	27	39
	Age at baseline	<18	92	70	22	.	24	5	6	11	13	7	11	15
		18-19	34	26	7	1	7	1	5	7	4	3	4	3
		20-24	96	78	18	.	22	13	10	19	10	8	2	12
		25-29	91	63	27	1	30	6	12	16	12	3	6	6
		30-34	55	38	17	.	22	6	6	9	3	4	2	3
		35+	12	7	5	.	6	.	.	1	3	.	2	.
	Years since diagnosis	5-9	47	40	7	.	8	2	2	5	9	4	7	10
		10-14	137	98	38	1	42	8	17	25	16	10	7	12
		15-19	116	86	29	1	33	11	12	22	10	8	10	10
		20+	80	58	22	.	28	10	8	11	10	3	3	7
	Age at diagnosis	<1	7	7	.	.	.	1	.	2	.	.	1	3
		1-4	111	84	27	.	29	11	12	9	12	8	14	16

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines ²			
			All cases	None	100-<250 mg/m2	250-<400 mg/m2	Unknown
Both sexes	All cases		979	947	9	14	9
	Age at baseline	<18	233	229	1	1	2
		18-19	77	76	.	.	1
		20-24	273	266	1	3	3
		25-29	236	226	4	4	2
		30-34	126	118	3	5	.
		35+	34	32	.	1	1
	Years since diagnosis	5-9	119	115	1	.	3
		10-14	333	327	4	1	1
		15-19	323	307	3	9	4
		20+	204	198	1	4	1
	Age at diagnosis	<1	23	23	.	.	.
		1-4	279	273	1	3	2
		5-9	402	390	2	6	4
		10-14	217	208	4	3	2
		15-20	58	53	2	2	1
Males	All cases		599	581	5	7	6
	Age at baseline	<18	141	139	1	.	1
		18-19	43	43	.	.	.
		20-24	177	171	1	2	3
		25-29	145	140	2	2	1
		30-34	71	67	1	3	.
		35+	22	21	.	.	1
	Years since diagnosis	5-9	72	69	1	.	2
		10-14	196	193	2	1	.
		15-19	207	198	2	4	3
		20+	124	121	.	2	1
	Age at diagnosis	<1	16	16	.	.	.
		1-4	168	166	.	1	1
		5-9	257	249	2	3	3
		10-14	123	119	1	2	1
		15-20	35	31	2	1	1
Females	All cases		380	366	4	7	3
	Age at baseline	<18	92	90	.	1	1
		18-19	34	33	.	.	1
		20-24	96	95	.	1	.
		25-29	91	86	2	2	1
		30-34	55	51	2	2	.
		35+	12	11	.	1	.
	Years since diagnosis	5-9	47	46	.	.	1
		10-14	137	134	2	.	1
		15-19	116	109	1	5	1
		20+	80	77	1	2	.
	Age at diagnosis	<1	7	7	.	.	.
		1-4	111	107	1	2	1

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	145	108	36	1	43	15	16	32	19	9	4	7
		10-14	94	68	25	1	30	4	9	16	12	7	6	10
		15-20	23	15	8	.	9	.	2	4	2	1	2	3

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines ²			
			All cases	None	100-<250 mg/m2	250-<400 mg/m2	Unknown
		5-9	145	141	.	3	1
		10-14	94	89	3	1	1
		15-20	23	22	.	1	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Any chemotherapy				Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	All cases	2827	2130	661	36	940	138	604	376	242	66	83	378	
	Age at baseline	<18	55	45	10	.	20	.	13	6	3	2	3	8
		18-19	55	45	10	.	17	1	17	7	6	.	1	6
		20-24	328	266	56	6	93	11	77	41	46	7	12	41
		25-29	733	588	137	8	211	21	207	110	66	22	18	78
		30-34	862	673	178	11	268	61	177	111	78	20	32	115
		35+	794	513	270	11	331	44	113	101	43	15	17	130
	Years since diagnosis	5-9	221	176	41	4	71	5	37	21	21	8	15	43
		10-14	867	684	173	10	268	31	241	118	81	15	17	96
		15-19	930	723	194	13	303	51	189	129	80	27	22	129
		20+	809	547	253	9	298	51	137	108	60	16	29	110
	Age at diagnosis	1-4	71	51	19	1	26	1	18	11	7	2	.	6
		5-9	353	280	71	2	109	18	82	45	39	9	11	40
		10-14	1026	830	184	12	276	46	260	156	115	25	34	114
		15-20	1377	969	387	21	529	73	244	164	81	30	38	218
Males	All cases	1458	1102	339	17	482	79	294	185	126	46	50	196	
	Age at baseline	<18	42	34	8	.	16	.	11	3	1	2	3	6
		18-19	44	35	9	.	14	1	13	6	4	.	1	5
		20-24	207	164	38	5	61	8	52	19	27	5	9	26
		25-29	401	317	79	5	120	15	86	68	41	16	10	45
		30-34	429	335	91	3	133	38	84	47	37	13	16	61
		35+	335	217	114	4	138	17	48	42	16	10	11	53
	Years since diagnosis	5-9	126	100	23	3	39	4	19	11	12	7	11	23
		10-14	441	347	90	4	139	16	111	60	41	9	13	52
		15-19	492	386	99	7	155	31	95	64	43	18	11	75
		20+	399	269	127	3	149	28	69	50	30	12	15	46
	Age at diagnosis	1-4	52	38	13	1	19	1	13	7	5	1	.	6
		5-9	259	203	54	2	81	15	60	29	28	9	6	31
		10-14	522	417	99	6	153	24	127	76	56	15	18	53
		15-20	625	444	173	8	229	39	94	73	37	21	26	106
Females	All cases	1369	1028	322	19	458	59	310	191	116	20	33	182	
	Age at baseline	<18	13	11	2	.	4	.	2	3	2	.	.	2
		18-19	11	10	1	.	3	.	4	1	2	.	.	1
		20-24	121	102	18	1	32	3	25	22	19	2	3	15
		25-29	332	271	58	3	91	6	121	42	25	6	8	33
		30-34	433	338	87	8	135	23	93	64	41	7	16	54
		35+	459	296	156	7	193	27	65	59	27	5	6	77
	Years since diagnosis	5-9	95	76	18	1	32	1	18	10	9	1	4	20
		10-14	426	337	83	6	129	15	130	58	40	6	4	44
		15-19	438	337	95	6	148	20	94	65	37	9	11	54
		20+	410	278	126	6	149	23	68	58	30	4	14	64
	Age at diagnosis	1-4	19	13	6	.	7	.	5	4	2	1	.	.
		5-9	94	77	17	.	28	3	22	16	11	.	5	9
		10-14	504	413	85	6	123	22	133	80	59	10	16	61
		15-20	752	525	214	13	300	34	150	91	44	9	12	112

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines ²					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	All cases	2827	1434	82	864	319	31	97	
	Age at baseline	<18	55	19	1	21	12	.	2
		18-19	55	21	3	19	10	1	1
		20-24	328	128	16	122	47	3	12
		25-29	733	322	22	296	65	3	25
		30-34	862	421	29	270	100	11	31
		35+	794	523	11	136	85	13	26
	Years since diagnosis	5-9	221	89	8	59	44	5	16
		10-14	867	364	22	362	86	4	29
		15-19	930	481	33	281	97	10	28
		20+	809	500	19	162	92	12	24
	Age at diagnosis	1-4	71	39	3	22	7	.	.
		5-9	353	166	13	122	42	3	7
		10-14	1026	458	41	356	131	11	29
		15-20	1377	771	25	364	139	17	61
Males	All cases	1458	741	49	434	166	20	48	
	Age at baseline	<18	42	13	.	19	8	.	2
		18-19	44	17	3	15	8	.	1
		20-24	207	83	13	71	30	2	8
		25-29	401	193	13	143	37	2	13
		30-34	429	205	18	130	52	10	14
		35+	335	230	2	56	31	6	10
	Years since diagnosis	5-9	126	52	2	34	25	3	10
		10-14	441	189	13	174	48	3	14
		15-19	492	253	25	140	50	8	16
		20+	399	247	9	86	43	6	8
	Age at diagnosis	1-4	52	28	3	15	6	.	.
		5-9	259	122	12	87	28	3	7
		10-14	522	229	26	176	71	5	15
		15-20	625	362	8	156	61	12	26
Females	All cases	1369	693	33	430	153	11	49	
	Age at baseline	<18	13	6	1	2	4	.	.
		18-19	11	4	.	4	2	1	.
		20-24	121	45	3	51	17	1	4
		25-29	332	129	9	153	28	1	12
		30-34	433	216	11	140	48	1	17
		35+	459	293	9	80	54	7	16
	Years since diagnosis	5-9	95	37	6	25	19	2	6
		10-14	426	175	9	188	38	1	15
		15-19	438	228	8	141	47	2	12
		20+	410	253	10	76	49	6	16
	Age at diagnosis	1-4	19	11	.	7	1	.	.
		5-9	94	44	1	35	14	.	.
		10-14	504	229	15	180	60	6	14
		15-20	752	409	17	208	78	5	35

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Any chemotherapy				Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	All cases	1915	1850	54	11	186	387	525	345	140	92	81	159	
	Age at baseline	<18	200	195	5	.	15	42	48	43	25	11	6	10
		18-19	119	117	1	1	4	23	35	21	12	9	3	12
		20-24	405	402	2	1	32	86	120	68	29	25	20	25
		25-29	526	511	10	5	46	108	140	101	42	25	17	47
		30-34	438	429	9	.	50	76	135	78	23	16	27	33
		35+	227	196	27	4	39	52	47	34	9	6	8	32
	Years since diagnosis	5-9	132	131	1	.	10	19	40	20	13	12	4	14
		10-14	609	591	16	2	55	132	169	119	51	34	13	36
		15-19	657	644	9	4	61	138	175	130	38	26	34	55
		20+	517	484	28	5	60	98	141	76	38	20	30	54
	Age at diagnosis	<1	12	10	2	.	3	3	2	1	.	.	2	1
		1-4	315	309	4	2	20	56	88	68	32	16	11	24
		5-9	579	570	6	3	46	121	150	101	49	35	28	49
		10-14	602	593	7	2	48	122	181	112	45	27	26	41
		15-20	407	368	35	4	69	85	104	63	14	14	14	44
Males	All cases	1290	1243	41	6	125	247	391	230	88	61	56	92	
	Age at baseline	<18	138	135	3	.	10	27	37	33	14	8	4	5
		18-19	87	85	1	1	2	15	29	16	8	7	2	8
		20-24	264	262	2	.	21	51	87	43	17	21	12	12
		25-29	367	357	7	3	30	69	104	72	31	16	14	31
		30-34	286	278	8	.	33	54	99	47	11	6	18	18
		35+	148	126	20	2	29	31	35	19	7	3	6	18
	Years since diagnosis	5-9	99	98	1	.	6	14	31	16	10	10	4	8
		10-14	413	402	10	1	34	78	131	85	32	27	7	19
		15-19	426	417	8	1	41	89	125	86	21	15	22	27
		20+	352	326	22	4	44	66	104	43	25	9	23	38
	Age at diagnosis	<1	3	1	2	.	2	.	1
		1-4	211	207	3	1	14	35	65	46	16	11	9	15
		5-9	404	396	5	3	29	85	114	70	33	20	19	34
		10-14	409	404	5	.	33	75	136	71	30	22	19	23
		15-20	263	235	26	2	47	52	75	43	9	8	9	20
Females	All cases	625	607	13	5	61	140	134	115	52	31	25	67	
	Age at baseline	<18	62	60	2	.	5	15	11	10	11	3	2	5
		18-19	32	32	.	.	2	8	6	5	4	2	1	4
		20-24	141	140	.	1	11	35	33	25	12	4	8	13
		25-29	159	154	3	2	16	39	36	29	11	9	3	16
		30-34	152	151	1	.	17	22	36	31	12	10	9	15
		35+	79	70	7	2	10	21	12	15	2	3	2	14
	Years since diagnosis	5-9	33	33	.	.	4	5	9	4	3	2	.	6
		10-14	196	189	6	1	21	54	38	34	19	7	6	17
		15-19	231	227	1	3	20	49	50	44	17	11	12	28
		20+	165	158	6	1	16	32	37	33	13	11	7	16
	Age at diagnosis	<1	9	9	.	.	1	3	1	1	.	.	2	1
		1-4	104	102	1	1	6	21	23	22	16	5	2	9

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Anthracyclines ²						
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	All cases		1915	515	172	797	224	97	110
	Age at baseline	<18	200	50	16	97	23	6	8
		18-19	119	25	17	46	16	5	10
		20-24	405	104	39	188	39	18	17
		25-29	526	141	46	234	54	21	30
		30-34	438	120	36	167	58	32	25
		35+	227	75	18	65	34	15	20
	Years since diagnosis	5-9	132	33	6	50	25	8	10
		10-14	609	136	56	294	63	26	34
		15-19	657	171	81	258	75	37	35
		20+	517	175	29	195	61	26	31
	Age at diagnosis	<1	12	4	2	4	1	1	.
		1-4	315	87	26	143	34	11	14
		5-9	579	159	57	247	57	26	33
		10-14	602	165	49	263	66	30	29
		15-20	407	100	38	140	66	29	34
Males	All cases		1290	373	107	544	147	59	60
	Age at baseline	<18	138	37	10	67	17	4	3
		18-19	87	22	10	34	9	4	8
		20-24	264	70	22	128	24	12	8
		25-29	367	103	36	164	36	13	15
		30-34	286	84	19	109	37	21	16
		35+	148	57	10	42	24	5	10
	Years since diagnosis	5-9	99	25	6	40	19	5	4
		10-14	413	103	39	195	38	21	17
		15-19	426	117	45	177	51	19	17
		20+	352	128	17	132	39	14	22
	Age at diagnosis	<1	3	2	.	.	1	.	.
		1-4	211	62	16	94	22	8	9
		5-9	404	111	36	184	35	16	22
		10-14	409	123	30	179	43	19	15
		15-20	263	75	25	87	46	16	14
Females	All cases		625	142	65	253	77	38	50
	Age at baseline	<18	62	13	6	30	6	2	5
		18-19	32	3	7	12	7	1	2
		20-24	141	34	17	60	15	6	9
		25-29	159	38	10	70	18	8	15
		30-34	152	36	17	58	21	11	9
		35+	79	18	8	23	10	10	10
	Years since diagnosis	5-9	33	8	.	10	6	3	6
		10-14	196	33	17	99	25	5	17
		15-19	231	54	36	81	24	18	18
		20+	165	47	12	63	22	12	9
	Age at diagnosis	<1	9	2	2	4	.	1	.
		1-4	104	25	10	49	12	3	5

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	175	174	1	.	17	36	36	31	16	15	9	15
		10-14	193	189	2	2	15	47	45	41	15	5	7	18
		15-20	144	133	9	2	22	33	29	20	5	6	5	24

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines ²					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	175	48	21	63	22	10	11
		10-14	193	42	19	84	23	11	14
		15-20	144	25	13	53	20	13	20

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Any chemotherapy				Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	All cases	2070	2030	38	2	1836	40	67	38	30	8	26	25	
	Age at baseline	<18	761	741	20	.	671	20	29	15	5	3	11	7
		18-19	275	269	6	.	242	7	13	5	5	1	1	1
		20-24	611	603	7	1	547	8	18	10	12	2	7	7
		25-29	342	339	3	.	305	5	6	7	5	2	5	7
		30-34	66	64	1	1	59	.	1	.	3	.	1	2
		35+	15	14	1	.	12	.	.	1	.	.	1	1
	Years since diagnosis	5-9	167	165	2	.	139	2	6	2	3	.	8	7
		10-14	675	661	14	.	585	21	33	16	6	4	5	5
		15-19	679	665	13	1	597	11	23	15	15	2	9	7
		20+	549	539	9	1	515	6	5	5	6	2	4	6
	Age at diagnosis	<1	301	273	27	1	283	6	2	4	2	1	1	2
		1-4	1261	1253	8	.	1141	24	40	21	13	4	11	7
		5-9	434	432	2	.	363	8	21	11	10	2	12	7
		10-14	54	53	.	1	36	1	4	1	4	1	1	6
		15-20	20	19	1	.	13	1	.	1	1	.	1	3
Males	All cases	917	898	18	1	817	15	28	18	14	3	12	10	
	Age at baseline	<18	369	358	11	.	321	9	17	7	4	2	6	3
		18-19	111	107	4	.	98	4	4	3	1	.	1	.
		20-24	252	249	2	1	233	1	5	3	6	.	1	3
		25-29	152	151	1	.	134	1	2	5	2	1	4	3
		30-34	27	27	.	.	26	.	.	.	1	.	.	.
		35+	6	6	.	.	5	1
	Years since diagnosis	5-9	74	73	1	.	58	.	4	2	3	.	5	2
		10-14	307	299	8	.	270	10	15	4	1	2	3	2
		15-19	289	282	7	.	259	4	7	8	6	.	3	2
		20+	247	244	2	1	230	1	2	4	4	1	1	4
	Age at diagnosis	<1	149	135	13	1	140	4	.	2	2	.	.	1
		1-4	564	559	5	.	511	8	19	10	7	2	5	2
		5-9	177	177	.	.	149	2	7	5	4	1	6	3
		10-14	19	19	.	.	12	1	2	1	.	.	.	3
		15-20	8	8	.	.	5	.	.	.	1	.	1	1
Females	All cases	1153	1132	20	1	1019	25	39	20	16	5	14	15	
	Age at baseline	<18	392	383	9	.	350	11	12	8	1	1	5	4
		18-19	164	162	2	.	144	3	9	2	4	1	.	1
		20-24	359	354	5	.	314	7	13	7	6	2	6	4
		25-29	190	188	2	.	171	4	4	2	3	1	1	4
		30-34	39	37	1	1	33	.	1	.	2	.	1	2
		35+	9	8	1	.	7	.	.	1	.	.	1	.
	Years since diagnosis	5-9	93	92	1	.	81	2	2	.	.	.	3	5
		10-14	368	362	6	.	315	11	18	12	5	2	2	3
		15-19	390	383	6	1	338	7	16	7	9	2	6	5
		20+	302	295	7	.	285	5	3	1	2	1	3	2
	Age at diagnosis	<1	152	138	14	.	143	2	2	2	.	1	1	1
		1-4	697	694	3	.	630	16	21	11	6	2	6	5

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines ²					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	All cases	2070	1117	83	470	325	25	50	
	Age at baseline	<18	761	386	35	179	131	11	19
		18-19	275	138	14	72	42	1	8
		20-24	611	343	14	137	95	7	15
		25-29	342	205	17	64	45	4	7
		30-34	66	36	3	13	12	1	1
		35+	15	9	.	5	.	1	.
	Years since diagnosis	5-9	167	79	3	34	41	2	8
		10-14	675	328	38	168	116	9	16
		15-19	679	356	22	183	97	6	15
		20+	549	354	20	85	71	8	11
	Age at diagnosis	<1	301	228	8	38	15	5	7
		1-4	1261	665	55	295	212	10	24
		5-9	434	198	17	114	83	8	14
		10-14	54	17	3	16	12	2	4
		15-20	20	9	.	7	3	.	1
Males	All cases	917	514	28	205	137	13	20	
	Age at baseline	<18	369	193	9	94	58	5	10
		18-19	111	63	4	26	13	1	4
		20-24	252	146	6	49	44	4	3
		25-29	152	95	8	28	17	2	2
		30-34	27	13	1	7	5	.	1
		35+	6	4	.	1	.	1	.
	Years since diagnosis	5-9	74	37	1	16	15	1	4
		10-14	307	159	10	75	51	4	8
		15-19	289	163	7	74	39	2	4
		20+	247	155	10	40	32	6	4
	Age at diagnosis	<1	149	115	2	22	7	1	2
		1-4	564	301	20	128	98	7	10
		5-9	177	89	5	48	25	4	6
		10-14	19	4	1	5	6	1	2
		15-20	8	5	.	2	1	.	.
Females	All cases	1153	603	55	265	188	12	30	
	Age at baseline	<18	392	193	26	85	73	6	9
		18-19	164	75	10	46	29	.	4
		20-24	359	197	8	88	51	3	12
		25-29	190	110	9	36	28	2	5
		30-34	39	23	2	6	7	1	.
		35+	9	5	.	4	.	.	.
	Years since diagnosis	5-9	93	42	2	18	26	1	4
		10-14	368	169	28	93	65	5	8
		15-19	390	193	15	109	58	4	11
		20+	302	199	10	45	39	2	7
	Age at diagnosis	<1	152	113	6	16	8	4	5
		1-4	697	364	35	167	114	3	14

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	257	255	2	.	214	6	14	6	6	1	6	4
		10-14	35	34	.	1	24	.	2	.	4	1	1	3
		15-20	12	11	1	.	8	1	.	1	.	.	.	2

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Anthracyclines ²						
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	257	109	12	66	58	4	8
		10-14	35	13	2	11	6	1	2
		15-20	12	4	.	5	2	.	1

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Any chemotherapy				Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	All cases		1798	1095	690	13	711	179	310	127	118	74	116	163
	Age at baseline	<18	889	547	337	5	346	112	160	65	47	25	54	80
		18-19	216	126	90	.	92	19	45	15	11	11	8	15
		20-24	504	313	188	3	196	35	88	35	47	25	31	47
		25-29	150	85	62	3	64	9	15	10	7	9	18	18
		30-34	34	22	10	2	10	4	2	2	5	3	5	3
		35+	5	2	3	.	3	.	.	.	1	1	.	.
	Years since diagnosis	5-9	152	111	39	2	42	14	21	16	6	6	20	27
		10-14	558	331	227	.	233	72	101	36	36	17	26	37
		15-19	594	347	242	5	246	57	107	45	40	28	27	44
		20+	494	306	182	6	190	36	81	30	36	23	43	55
	Age at diagnosis	<1	912	528	380	4	390	127	179	62	38	13	39	64
		1-4	706	455	245	6	254	45	117	53	64	47	56	70
		5-9	137	89	46	2	48	4	11	10	12	10	17	25
		10-14	27	14	12	1	12	2	2	2	2	2	2	3
		15-20	16	9	7	.	7	1	1	.	2	2	2	1
Males	All cases		870	538	326	6	334	89	151	56	55	45	64	76
	Age at baseline	<18	440	276	162	2	164	57	81	33	21	12	31	41
		18-19	94	58	36	.	36	6	21	5	6	9	5	6
		20-24	255	148	104	3	109	17	37	13	23	18	17	21
		25-29	65	43	21	1	22	6	11	5	1	4	9	7
		30-34	14	12	2	.	2	3	1	.	3	2	2	1
		35+	2	1	1	.	1	.	.	.	1	.	.	.
	Years since diagnosis	5-9	72	52	19	1	20	8	11	7	1	2	10	13
		10-14	274	167	107	.	108	38	48	20	17	8	16	19
		15-19	283	170	111	2	113	21	54	17	19	23	17	19
		20+	241	149	89	3	93	22	38	12	18	12	21	25
	Age at diagnosis	<1	470	267	201	2	205	68	89	32	17	7	22	30
		1-4	317	211	103	3	106	18	55	18	29	29	29	33
		5-9	67	51	15	1	16	2	7	5	8	6	10	13
		10-14	10	5	5	.	5	.	.	1	.	2	2	.
		15-20	6	4	2	.	2	1	.	.	1	1	1	.
Females	All cases		928	557	364	7	377	90	159	71	63	29	52	87
	Age at baseline	<18	449	271	175	3	182	55	79	32	26	13	23	39
		18-19	122	68	54	.	56	13	24	10	5	2	3	9
		20-24	249	165	84	.	87	18	51	22	24	7	14	26
		25-29	85	42	41	2	42	3	4	5	6	5	9	11
		30-34	20	10	8	2	8	1	1	2	2	1	3	2
		35+	3	1	2	.	2	1	.	.
	Years since diagnosis	5-9	80	59	20	1	22	6	10	9	5	4	10	14
		10-14	284	164	120	.	125	34	53	16	19	9	10	18
		15-19	311	177	131	3	133	36	53	28	21	5	10	25
		20+	253	157	93	3	97	14	43	18	18	11	22	30
	Age at diagnosis	<1	442	261	179	2	185	59	90	30	21	6	17	34
		1-4	389	244	142	3	148	27	62	35	35	18	27	37

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Anthracyclines ²						
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	All cases		1798	1032	137	418	104	38	69
	Age at baseline	<18	889	473	99	218	55	10	34
		18-19	216	127	6	54	11	7	11
		20-24	504	306	25	116	28	13	16
		25-29	150	101	6	23	8	5	7
		30-34	34	22	1	6	2	2	1
		35+	5	3	.	1	.	1	.
	Years since diagnosis	5-9	152	61	14	40	20	6	11
		10-14	558	301	62	147	25	6	17
		15-19	594	347	39	137	37	10	24
		20+	494	323	22	94	22	16	17
	Age at diagnosis	<1	912	575	83	186	30	16	22
		1-4	706	364	48	191	56	13	34
		5-9	137	70	4	33	15	5	10
		10-14	27	15	1	4	2	2	3
		15-20	16	8	1	4	1	2	.
Males	All cases		870	474	72	223	55	16	30
	Age at baseline	<18	440	221	53	116	30	3	17
		18-19	94	50	3	29	6	2	4
		20-24	255	154	13	58	14	8	8
		25-29	65	41	2	15	4	2	1
		30-34	14	7	1	4	1	1	.
		35+	2	1	.	1	.	.	.
	Years since diagnosis	5-9	72	27	4	19	12	3	7
		10-14	274	141	36	79	11	1	6
		15-19	283	155	22	72	22	3	9
		20+	241	151	10	53	10	9	8
	Age at diagnosis	<1	470	288	45	105	14	7	11
		1-4	317	150	25	96	27	4	15
		5-9	67	29	2	18	11	3	4
		10-14	10	5	.	2	2	1	.
		15-20	6	2	.	2	1	1	.
Females	All cases		928	558	65	195	49	22	39
	Age at baseline	<18	449	252	46	102	25	7	17
		18-19	122	77	3	25	5	5	7
		20-24	249	152	12	58	14	5	8
		25-29	85	60	4	8	4	3	6
		30-34	20	15	.	2	1	1	1
		35+	3	2	.	.	.	1	.
	Years since diagnosis	5-9	80	34	10	21	8	3	4
		10-14	284	160	26	68	14	5	11
		15-19	311	192	17	65	15	7	15
		20+	253	172	12	41	12	7	9
	Age at diagnosis	<1	442	287	38	81	16	9	11
		1-4	389	214	23	95	29	9	19

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	70	38	31	1	32	2	4	5	4	4	7	12
		10-14	17	9	7	1	7	2	2	1	2	.	.	3
		15-20	10	5	5	.	5	.	1	.	1	1	1	1

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Anthracyclines ²						
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	70	41	2	15	4	2	6
		10-14	17	10	1	2	.	1	3
		15-20	10	6	1	2	.	1	.

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Any chemotherapy				Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	All cases		1588	1340	237	11	451	68	103	162	148	150	357	149
	Age at baseline	<18	313	289	23	1	62	12	21	39	45	37	74	23
		18-19	115	106	8	1	22	4	7	16	9	21	28	8
		20-24	382	341	39	2	88	14	22	38	41	39	102	38
		25-29	351	299	49	3	102	16	26	33	35	31	76	32
		30-34	264	203	60	1	96	14	12	24	13	17	59	29
		35+	163	102	58	3	81	8	15	12	5	5	18	19
	Years since diagnosis	5-9	165	137	27	1	45	8	15	15	20	16	27	19
		10-14	473	397	74	2	132	19	33	55	48	45	107	34
		15-19	498	440	56	2	117	22	30	56	44	55	127	47
		20+	452	366	80	6	157	19	25	36	36	34	96	49
	Age at diagnosis	<1	108	86	21	1	40	6	5	10	13	12	14	8
		1-4	507	484	20	3	84	14	37	62	61	66	137	46
		5-9	361	326	34	1	90	18	16	36	35	36	101	29
		10-14	311	248	59	4	99	12	19	26	26	22	72	35
		15-20	301	196	103	2	138	18	26	28	13	14	33	31
Males	All cases		847	736	107	4	233	37	60	75	75	76	210	81
	Age at baseline	<18	179	170	9	.	28	8	15	20	25	16	52	15
		18-19	58	55	3	.	10	1	3	9	3	15	14	3
		20-24	213	188	24	1	57	8	12	18	21	17	58	22
		25-29	179	158	20	1	50	10	13	13	17	16	45	15
		30-34	139	112	26	1	49	7	8	8	8	10	33	16
		35+	79	53	25	1	39	3	9	7	1	2	8	10
	Years since diagnosis	5-9	89	77	12	.	21	4	9	7	11	7	19	11
		10-14	264	229	35	.	65	12	21	27	24	22	73	20
		15-19	252	228	22	2	62	14	14	24	21	30	64	23
		20+	242	202	38	2	85	7	16	17	19	17	54	27
	Age at diagnosis	<1	44	38	6	.	13	3	3	7	4	5	5	4
		1-4	293	280	12	1	50	6	23	31	38	34	82	29
		5-9	202	182	19	1	53	13	9	16	16	19	61	15
		10-14	167	139	26	2	53	7	11	9	12	12	45	18
		15-20	141	97	44	.	64	8	14	12	5	6	17	15
Females	All cases		741	604	130	7	218	31	43	87	73	74	147	68
	Age at baseline	<18	134	119	14	1	34	4	6	19	20	21	22	8
		18-19	57	51	5	1	12	3	4	7	6	6	14	5
		20-24	169	153	15	1	31	6	10	20	20	22	44	16
		25-29	172	141	29	2	52	6	13	20	18	15	31	17
		30-34	125	91	34	.	47	7	4	16	5	7	26	13
		35+	84	49	33	2	42	5	6	5	4	3	10	9
	Years since diagnosis	5-9	76	60	15	1	24	4	6	8	9	9	8	8
		10-14	209	168	39	2	67	7	12	28	24	23	34	14
		15-19	246	212	34	.	55	8	16	32	23	25	63	24
		20+	210	164	42	4	72	12	9	19	17	17	42	22
	Age at diagnosis	<1	64	48	15	1	27	3	2	3	9	7	9	4
		1-4	214	204	8	2	34	8	14	31	23	32	55	17

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Anthracyclines ²						
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	All cases	1588	929	34	127	255	182	61	
	Age at baseline	<18	313	162	8	30	65	40	8
		18-19	115	70	5	6	16	16	2
		20-24	382	234	2	31	66	36	13
		25-29	351	202	6	28	62	39	14
		30-34	264	162	7	20	31	30	14
		35+	163	99	6	12	15	21	10
	Years since diagnosis	5-9	165	66	1	19	45	26	8
		10-14	473	269	13	32	85	56	18
		15-19	498	297	11	41	69	63	17
		20+	452	297	9	35	56	37	18
	Age at diagnosis	<1	108	79	3	4	10	9	3
		1-4	507	285	12	47	90	58	15
		5-9	361	231	7	23	61	32	7
		10-14	311	166	3	28	51	45	18
		15-20	301	168	9	25	43	38	18
Males	All cases	847	495	21	65	140	94	32	
	Age at baseline	<18	179	88	6	20	42	19	4
		18-19	58	38	3	1	9	7	.
		20-24	213	134	1	14	37	20	7
		25-29	179	105	3	13	27	23	8
		30-34	139	86	3	9	18	14	9
		35+	79	44	5	8	7	11	4
	Years since diagnosis	5-9	89	31	.	12	25	17	4
		10-14	264	148	11	19	48	30	8
		15-19	252	155	5	14	42	28	8
		20+	242	161	5	20	25	19	12
	Age at diagnosis	<1	44	30	1	3	5	3	2
		1-4	293	167	8	21	58	31	8
		5-9	202	136	3	15	31	13	4
		10-14	167	85	3	14	23	32	10
		15-20	141	77	6	12	23	15	8
Females	All cases	741	434	13	62	115	88	29	
	Age at baseline	<18	134	74	2	10	23	21	4
		18-19	57	32	2	5	7	9	2
		20-24	169	100	1	17	29	16	6
		25-29	172	97	3	15	35	16	6
		30-34	125	76	4	11	13	16	5
		35+	84	55	1	4	8	10	6
	Years since diagnosis	5-9	76	35	1	7	20	9	4
		10-14	209	121	2	13	37	26	10
		15-19	246	142	6	27	27	35	9
		20+	210	136	4	15	31	18	6
	Age at diagnosis	<1	64	49	2	1	5	6	1
		1-4	214	118	4	26	32	27	7

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Any chemotherapy			Alkylating agent (CED, mg/m2) ¹							
		All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
	5-9	159	144	15	.	37	5	7	20	19	17	40	14
	10-14	144	109	33	2	46	5	8	17	14	10	27	17
	15-20	160	99	59	2	74	10	12	16	8	8	16	16

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Anthracyclines ²					
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	159	95	4	8	30	19	3
		10-14	144	81	.	14	28	13	8
		15-20	160	91	3	13	20	23	10

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	All cases		1931	1786	138	7	467	159	328	215	176	124	294	168
	Age at baseline	<18	85	84	1	.	5	5	9	6	12	6	25	17
		18-19	66	61	5	.	9	5	8	8	10	5	11	10
		20-24	359	346	12	1	44	29	68	41	31	33	74	39
		25-29	528	500	27	1	138	35	88	67	42	38	79	41
		30-34	517	472	43	2	151	46	86	54	52	19	77	32
		35+	376	323	50	3	120	39	69	39	29	23	28	29
	Years since diagnosis	5-9	214	207	6	1	20	16	53	17	21	13	30	44
		10-14	629	581	47	1	148	60	98	84	56	36	107	40
		15-19	633	593	37	3	171	42	102	67	60	40	106	45
		20+	455	405	48	2	128	41	75	47	39	35	51	39
	Age at diagnosis	<1	8	7	1	.	2	.	.	1	2	1	2	.
		1-4	80	78	2	.	10	4	7	4	11	8	27	9
		5-9	338	320	18	.	60	16	51	40	41	33	66	31
		10-14	774	732	39	3	180	69	129	85	65	51	121	74
		15-20	731	649	78	4	215	70	141	85	57	31	78	54
Males	All cases		978	916	58	4	224	73	173	115	87	63	159	84
	Age at baseline	<18	43	43	.	.	3	1	5	2	6	3	14	9
		18-19	33	30	3	.	5	3	2	6	6	2	3	6
		20-24	174	167	6	1	20	12	33	24	17	15	35	18
		25-29	274	260	13	1	73	15	43	37	22	22	40	22
		30-34	255	238	16	1	66	24	45	23	24	10	49	14
		35+	199	178	20	1	57	18	45	23	12	11	18	15
	Years since diagnosis	5-9	114	110	3	1	10	8	27	9	14	6	19	21
		10-14	318	295	22	1	81	23	55	47	27	15	47	23
		15-19	320	305	14	1	80	24	51	37	28	21	57	22
		20+	226	206	19	1	53	18	40	22	18	21	36	18
	Age at diagnosis	<1	4	4	.	.	1	.	.	1	.	.	2	.
		1-4	41	39	2	.	4	1	4	2	8	5	13	4
		5-9	173	163	10	.	29	7	24	24	17	20	36	16
		10-14	362	346	14	2	78	24	56	42	37	26	62	37
		15-20	398	364	32	2	112	41	89	46	25	12	46	27
Females	All cases		953	870	80	3	243	86	155	100	89	61	135	84
	Age at baseline	<18	42	41	1	.	2	4	4	4	6	3	11	8
		18-19	33	31	2	.	4	2	6	2	4	3	8	4
		20-24	185	179	6	.	24	17	35	17	14	18	39	21
		25-29	254	240	14	.	65	20	45	30	20	16	39	19
		30-34	262	234	27	1	85	22	41	31	28	9	28	18
		35+	177	145	30	2	63	21	24	16	17	12	10	14
	Years since diagnosis	5-9	100	97	3	.	10	8	26	8	7	7	11	23
		10-14	311	286	25	.	67	37	43	37	29	21	60	17
		15-19	313	288	23	2	91	18	51	30	32	19	49	23
		20+	229	199	29	1	75	23	35	25	21	14	15	21
	Age at diagnosis	<1	4	3	1	.	1	.	.	.	2	1	.	.
		1-4	39	39	.	.	6	3	3	2	3	3	14	5

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Anthracyclines ²						
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	All cases	1931	230	36	197	730	588	150	
	Age at baseline	<18	85	2	.	11	43	20	9
		18-19	66	7	1	4	27	20	7
		20-24	359	20	6	27	164	118	24
		25-29	528	51	10	54	203	163	47
		30-34	517	70	12	55	179	166	35
		35+	376	80	7	46	114	101	28
	Years since diagnosis	5-9	214	13	5	13	89	69	25
		10-14	629	59	8	68	259	200	35
		15-19	633	63	11	70	230	212	47
		20+	455	95	12	46	152	107	43
	Age at diagnosis	<1	8	2	1	4	1	.	.
		1-4	80	5	1	7	47	14	6
		5-9	338	30	6	29	142	101	30
		10-14	774	85	11	78	307	233	60
		15-20	731	108	17	79	233	240	54
Males	All cases	978	100	21	106	354	315	82	
	Age at baseline	<18	43	1	.	7	17	12	6
		18-19	33	5	1	2	11	11	3
		20-24	174	10	3	15	73	60	13
		25-29	274	23	4	30	98	90	29
		30-34	255	26	8	27	92	85	17
		35+	199	35	5	25	63	57	14
	Years since diagnosis	5-9	114	7	3	7	43	39	15
		10-14	318	26	3	38	120	109	22
		15-19	320	25	8	36	117	109	25
		20+	226	42	7	25	74	58	20
	Age at diagnosis	<1	4	1	1	1	1	.	.
		1-4	41	4	1	5	21	9	1
		5-9	173	17	2	17	67	53	17
		10-14	362	33	4	39	135	115	36
		15-20	398	45	13	44	130	138	28
Females	All cases	953	130	15	91	376	273	68	
	Age at baseline	<18	42	1	.	4	26	8	3
		18-19	33	2	.	2	16	9	4
		20-24	185	10	3	12	91	58	11
		25-29	254	28	6	24	105	73	18
		30-34	262	44	4	28	87	81	18
		35+	177	45	2	21	51	44	14
	Years since diagnosis	5-9	100	6	2	6	46	30	10
		10-14	311	33	5	30	139	91	13
		15-19	313	38	3	34	113	103	22
		20+	229	53	5	21	78	49	23
	Age at diagnosis	<1	4	1	.	3	.	.	.
		1-4	39	1	.	2	26	5	5

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	165	157	8	.	31	9	27	16	24	13	30	15
		10-14	412	386	25	1	102	45	73	43	28	25	59	37
		15-20	333	285	46	2	103	29	52	39	32	19	32	27

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Anthracyclines ²						
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	165	13	4	12	75	48	13
		10-14	412	52	7	39	172	118	24
		15-20	333	63	4	35	103	102	26

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
Both sexes	All cases	685	679	4	2	15	21	38	84	104	95	242	86	
	Age at baseline	<18	54	54	.	.	1	.	3	5	9	4	21	11
		18-19	33	33	.	.	.	2	.	5	9	4	8	5
		20-24	157	155	1	1	4	3	6	18	21	23	62	20
		25-29	193	193	.	.	4	7	12	25	20	33	69	23
		30-34	153	150	2	1	2	7	9	15	28	13	59	20
		35+	95	94	1	.	4	2	8	16	17	18	23	7
	Years since diagnosis	5-9	90	88	1	1	2	2	9	7	12	7	26	25
		10-14	231	231	.	.	4	10	8	39	39	29	86	16
		15-19	214	213	.	1	2	4	11	21	26	33	88	29
		20+	150	147	3	.	7	5	10	17	27	26	42	16
	Age at diagnosis	<1	4	4	.	.	1	.	.	1	1	1	.	
		1-4	50	50	.	.	1	.	1	2	10	7	21	8
		5-9	170	168	2	.	3	5	9	23	27	27	58	18
		10-14	257	254	2	1	9	11	9	26	33	35	99	35
		15-20	204	203	.	1	1	5	19	33	33	25	63	25
Males	All cases	353	350	2	1	7	11	20	44	55	47	133	36	
	Age at baseline	<18	24	24	.	.	1	.	.	1	5	1	12	4
		18-19	17	17	.	.	.	1	.	4	6	2	2	2
		20-24	78	77	.	1	1	2	2	10	12	11	29	11
		25-29	99	99	.	.	3	3	4	14	11	19	35	10
		30-34	83	82	1	.	1	4	7	5	14	7	39	6
		35+	52	51	1	.	1	1	7	10	7	7	16	3
	Years since diagnosis	5-9	48	47	.	1	1	1	2	3	9	3	17	12
		10-14	109	109	.	.	2	4	4	22	18	13	37	9
		15-19	115	115	.	.	2	4	6	12	15	16	49	11
		20+	81	79	2	.	2	2	8	7	13	15	30	4
	Age at diagnosis	<1	2	2	.	.	1	1	.
		1-4	26	26	8	4	11	3
		5-9	84	83	1	.	1	3	4	12	12	17	30	5
		10-14	135	133	1	1	4	5	4	15	21	17	52	17
		15-20	106	106	.	.	1	3	12	17	14	9	39	11
Females	All cases	332	329	2	1	8	10	18	40	49	48	109	50	
	Age at baseline	<18	30	30	3	4	4	3	9	7
		18-19	16	16	.	.	.	1	.	1	3	2	6	3
		20-24	79	78	1	.	3	1	4	8	9	12	33	9
		25-29	94	94	.	.	1	4	8	11	9	14	34	13
		30-34	70	68	1	1	1	3	2	10	14	6	20	14
		35+	43	43	.	.	3	1	1	6	10	11	7	4
	Years since diagnosis	5-9	42	41	1	.	1	1	7	4	3	4	9	13
		10-14	122	122	.	.	2	6	4	17	21	16	49	7
		15-19	99	98	.	1	.	.	5	9	11	17	39	18
		20+	69	68	1	.	5	3	2	10	14	11	12	12
	Age at diagnosis	<1	2	2	1	1	.	.
		1-4	24	24	.	.	1	.	1	2	2	3	10	5

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Anthracyclines ²						
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
Both sexes	All cases		685	57	10	60	332	172	54
	Age at baseline	<18	54	1	.	6	30	13	4
		18-19	33	2	1	4	14	9	3
		20-24	157	5	.	10	81	44	17
		25-29	193	14	5	16	103	41	14
		30-34	153	20	2	12	66	42	11
		35+	95	15	2	12	38	23	5
	Years since diagnosis	5-9	90	5	3	1	36	31	14
		10-14	231	5	3	25	126	64	8
		15-19	214	16	1	20	108	53	16
		20+	150	31	3	14	62	24	16
	Age at diagnosis	<1	4	1	.	3	.	.	.
		1-4	50	2	.	4	34	5	5
		5-9	170	12	1	14	87	39	17
		10-14	257	30	3	23	123	59	19
		15-20	204	12	6	16	88	69	13
Males	All cases		353	24	5	34	175	91	24
	Age at baseline	<18	24	1	.	4	11	7	1
		18-19	17	2	1	2	5	6	1
		20-24	78	1	.	6	41	21	9
		25-29	99	6	1	9	54	22	7
		30-34	83	6	1	6	43	23	4
		35+	52	8	2	7	21	12	2
	Years since diagnosis	5-9	48	2	2	1	17	18	8
		10-14	109	2	.	14	58	31	4
		15-19	115	4	1	10	64	29	7
		20+	81	16	2	9	36	13	5
	Age at diagnosis	<1	2	1	.	1	.	.	.
		1-4	26	2	.	3	17	4	.
		5-9	84	6	.	8	43	20	7
		10-14	135	12	2	14	68	29	10
		15-20	106	3	3	8	47	38	7
Females	All cases		332	33	5	26	157	81	30
	Age at baseline	<18	30	.	.	2	19	6	3
		18-19	16	.	.	2	9	3	2
		20-24	79	4	.	4	40	23	8
		25-29	94	8	4	7	49	19	7
		30-34	70	14	1	6	23	19	7
		35+	43	7	.	5	17	11	3
	Years since diagnosis	5-9	42	3	1	.	19	13	6
		10-14	122	3	3	11	68	33	4
		15-19	99	12	.	10	44	24	9
		20+	69	15	1	5	26	11	11
	Age at diagnosis	<1	2	.	.	2	.	.	.
		1-4	24	.	.	1	17	1	5

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

				Any chemotherapy			Alkylating agent (CED, mg/m2) ¹							
			All cases	Yes	No	Unknown	None	1-<4000 mg/m2	4000-<8000 mg/m2	8000-<12000 mg/m2	12000-<16000 mg/m2	16000-<20000 mg/m2	20000+ mg/m2	Unknown
		5-9	86	85	1	.	2	2	5	11	15	10	28	13
		10-14	122	121	1	.	5	6	5	11	12	18	47	18
		15-20	98	97	.	1	.	2	7	16	19	16	24	14

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)

			Anthracyclines ²						
			All cases	None	1-<100 mg/m2	100-<250 mg/m2	250-<400 mg/m2	400+ mg/m2	Unknown
		5-9	86	6	1	6	44	19	10
		10-14	122	18	1	9	55	30	9
		15-20	98	9	3	8	41	31	6

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years

¹ Includes all alkylators with dose info, other than cisplatin, carboplatin, DTIC and temozolomide

² Includes anthracyclines with dose info: doxorubicin, daunorubicin and idarubicin(x3)